"Jan. 22, 2013 -- Think a nightcap may help you get a better night's sleep?
A new review of 27 studies shows that alcohol does not improve sleep quality. According to the findings, alcohol does allow healthy people to fal"...
In OSA, NUVIGIL (armodafinil) is indicated as an adjunct to standard treatment(s) for the underlying obstruction. If continuous positive airway pressure (CPAP) is the treatment of choice for a patient, a maximal effort to treat with CPAP for an adequate period of time should be made prior to initiating NUVIGIL (armodafinil) . If NUVIGIL (armodafinil) is used adjunctively with CPAP, the encouragement of and periodic assessment of CPAP compliance is necessary.
In all cases, careful attention to the diagnosis and treatment of the underlying sleep disorder(s) is of utmost importance. Prescribers should be aware that some patients may have more than one sleep disorder contributing to their excessive sleepiness.
The effectiveness of NUVIGIL (armodafinil) in long-term use (greater than 12 weeks) has not been systematically evaluated in placebo-controlled trials. The physician who elects to prescribe NUVIGIL (armodafinil) for an extended time in patients should periodically re-evaluate long-term usefulness for the individual patient.
DOSAGE AND ADMINISTRATION
Obstructive Sleep Apnea (OSA) and Narcolepsy
The recommended dose of NUVIGIL (armodafinil) for patients with OSA or narcolepsy is 150 mg or 250 mg given as a single dose in the morning. In patients with OSA, doses up to 250 mg/day, given as a single dose, have been well tolerated, but there is no consistent evidence that this dose confers additional benefit beyond that of the 150 mg/day dose (See CLINICAL PHARMACOLOGY and Clinical Trials).
Shift Work Disorder (SWD)
The recommended dose of NUVIGIL (armodafinil) for patients with SWD is 150 mg given daily approximately 1 hour prior to the start of their work shift.
Dosage adjustment should be considered for concomitant medications that are substrates for CYP3A4/5, such as steroidal contraceptives, triazolam, and cyclosporine (See PRECAUTIONS: DRUG INTERACTIONS).
Drugs that are largely eliminated via CYP2C19 metabolism, such as diazepam, propranolol, and phenytoin may have prolonged elimination upon coadministration with NUVIGIL (armodafinil) and may require dosage reduction and monitoring for toxicity (See PRECAUTIONS: DRUG INTERACTIONS).
In elderly patients, elimination of armodafinil and its metabolites may be reduced as a consequence of aging. Therefore, consideration should be given to the use of lower doses in this population (See CLINICAL PHARMACOLOGY and PRECAUTIONS).
NUVIGIL® (armodafinil) Tablets [C-IV]
50 mg: Each round, white, uncoated tablet is debossed with "C" on one side and "205" on the other.
NDC 63459-205-60 - Bottles of 60
150 mg: Each oval, white, uncoated tablet is debossed with "C" on one side and "215" on the other.
NDC 63459-215-60 - Bottles of 60
250 mg: Each oval, white, uncoated tablet is debossed with "C" on one side and "225" on the other.
NDC 63459-225-60 - Bottles of 60
Store at 20° - 25° C (68° - 77° F).
Distributed by: Cephalon, Inc, Frazer, PA 19355. Revised: October 2010
Last reviewed on RxList: 1/14/2011
This monograph has been modified to include the generic and brand name in many instances.
Additional Nuvigil Information
Nuvigil - User Reviews
Nuvigil User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get tips for better sleep.